Introduction {#tca12645-sec-0005}
============

Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide and the third leading cause of cancer death.[1](#tca12645-bib-0001){ref-type="ref"} Metastasis and recurrence are the most common causes of death in CRC patients. The overall metastasis rate of CRC is approximately 50%. Nearly 25% of CRC patients have developed synchronous liver metastasis at the time of initial diagnosis, and 60--70% of CRC patients experience recurrence in the liver after local primary tumor resection.[2](#tca12645-bib-0002){ref-type="ref"} The lung is the second most frequent location of metastasis in CRC patients.[3](#tca12645-bib-0003){ref-type="ref"} At diagnosis, \> 10% of CRC patients may have pulmonary metastasis.[4](#tca12645-bib-0004){ref-type="ref"} Furthermore, lung metastasis occurs in 10--20% patients who undergo curative resection.[5](#tca12645-bib-0005){ref-type="ref"} Surgery remains the optimal option for the treatment of metastatic CRC. When surgical resection is possible, the five‐year survival rate approaches 35%.[6](#tca12645-bib-0006){ref-type="ref"} However, only 20--35% patients with metastatic CRC are eligible for surgery,[2](#tca12645-bib-0002){ref-type="ref"} and relapse is common, occurring in approximately 75% of such patients.[7](#tca12645-bib-0007){ref-type="ref"} To improve long‐term survival, early and timely identification of patients at high risk of metastatic dissemination is therefore required.

Cancer progression involves constant and dynamic interaction between tumor cells and components of the surrounding extracellular matrix (ECM),[8](#tca12645-bib-0008){ref-type="ref"} a substance formed by macromolecules that provides structural and biochemical support to cancer cells, vessels, and surrounding stromal cells. LOX is a member of the secreted copper‐dependent amine oxidase family that plays a central role in ECM remodeling and maturation by mediating the cross‐linking of collagen and elastin in ECM.[9](#tca12645-bib-0009){ref-type="ref"} The LOX multigene family comprises five members (LOX, LOXL1, LOXL2, LOXL3, and LOXL4), all of which share a highly conserved homologue sequence within their carboxy terminal region.[10](#tca12645-bib-0010){ref-type="ref"} LOX is an important ECM whose matrix remodeling function has been studied extensively.[11](#tca12645-bib-0011){ref-type="ref"} Elevated LOX expression is reported to be associated with invasion and metastasis in various types of solid tumors, such as breast,[12](#tca12645-bib-0012){ref-type="ref"}, [13](#tca12645-bib-0013){ref-type="ref"} melanoma,[14](#tca12645-bib-0014){ref-type="ref"} and head and neck tumors.[15](#tca12645-bib-0015){ref-type="ref"}

The role of LOX in CRC has recently been comprehensively investigated, but the results reported are conflicting.[11](#tca12645-bib-0011){ref-type="ref"}, [16](#tca12645-bib-0016){ref-type="ref"} Csiszar *et al*. reported that LOX messenger RNA (mRNA) expression is decreased in CRC patients with non‐metastatic disease, suggesting that LOX functions as a tumor suppressor.[17](#tca12645-bib-0017){ref-type="ref"} However, a later study by Baker *et al*. showed that LOX expression is significantly elevated in tumor tissues, suggesting that it functions as a tumor promoter.[16](#tca12645-bib-0016){ref-type="ref"} Therefore, the role of LOX and its correlation with clinicopathological features in CRC remains inconclusive.[18](#tca12645-bib-0018){ref-type="ref"} The intracellular function of LOX in CRC also remains unclear. The aim of the present study was to determine whether LOX is involved in the regulation of cancer cell differentiation, migration, and adhesion, and to clarify the role of LOX nuclear localization in CRC.

Materials {#tca12645-sec-0006}
=========

Patients {#tca12645-sec-0007}
--------

Two hundred and one CRC patients who were admitted and received treatment at Xinhua Hospital of Shanghai Jiaotong University School of Medicine (Shanghai, China) between January 2008 and December 2012 were enrolled in the study. The institutional review board of the hospital approved the research protocol, and informed consent was obtained from all patients. Eight CRC specimens and paired normal colorectal tissues were used for real‐time PCR analysis. Normal colon mucosa and CRC specimens were used for tissue microarray construction and immunohistochemical analysis. All patients underwent surgery and were followed‐up postoperatively on an outpatient basis every three months for the first two years. Follow‐up examination included chest X‐ray; abdominal ultrasound; computed tomography (CT) scans of the thorax, abdomen, and pelvis; and blood biochemistry, including carcinoembryonic antigen (CEA). In the three to five years following surgery, follow‐up examinations were performed every six months.

Cells culture, transfection, infection and 5‐aza‐dC treatment {#tca12645-sec-0008}
-------------------------------------------------------------

CRC HCT116 and LoVo cells were cultured in Dulbecco\'s modified Eagle medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in a 5% CO~2~ atmosphere. Transfection was performed using Lipofectamine 2000 according to manufacturer guidelines (Invitrogen, Carlsbad, CA, USA). Stable cells were established by lentiviral or retroviral transduction and selected in 2 μg/mL puromycin or 200 μg/mL hygromycin, respectively, for two to three weeks to achieve stable knockdown or overexpression. Cells were seeded at 3 × 10^5^ cells per well in six‐well plates 24 hours before 5‐aza‐dC treatment. Different concentrations of 5‐aza‐dC were added to the medium (1 μM and 5 μM), which were harvested in 48 hours. Total RNA was isolated and the LOX mRNA level was detected by quantitative real‐time PCR (qRT‐PCR).

RNA isolation and quantitative real‐time‐PCR {#tca12645-sec-0009}
--------------------------------------------

Total RNA was extracted using RNAiso Plus (TaKaRa, Dalian, China) and retro‐transcribed into cDNA using a PrimeScript RT‐PCR Kit (TaKaRa). qRT was performed using SYBR Premix Ex Taq (TaKaRa) on ABI 7500. Glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) was used

as an internal control. The sequences for qRT‐PCR primers were as follows: GAPDH forward, 5′‐GTCATCCAACGGGAATGCA‐3′; GAPDH reverse, 5′‐TGATCGGTTA CCGTGATCAAAA‐3′; LOX forward, 5′‐TGGCAGTCTATGTCTGCACC‐3′; LOX reverse, 5′‐ CTATGGCTACCACAGGCGAT‐3′; TEAD4 forward, 5′‐ GTATGAGAGCCCCGAGAACAT‐3′; TEAD4 reverse, 5′‐ GGATGCGGTAAGAGTAGTGTCC‐3′.

Western blotting {#tca12645-sec-0010}
----------------

Cells were harvested and lysed with 1% NP‐40 lysis buffer. An equal amount of protein was separated on 10% sodium dodecyl sulfate‐polyacrylamide gel electrophoresis and transferred to the nitrocellulose membrane. The membrane was blocked with 5% milk, followed by incubation with the following primary antibodies at 4°C overnight: LOX (1:1000; Proteintech, Chicago, IL, USA), YAP (1:1000; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and β‐ACTIN (1:1000; Sigma‐Aldrich, St Louis, MO, USA). After washing, the membrane was incubated with horseradish peroxidase‐labeled secondary antibodies. The proteins were visualized using enhanced chemiluminescence reagents (Millipore, Billerica, MA, USA).

Immunohistochemistry {#tca12645-sec-0011}
--------------------

For immunohistochemical staining, sections were de‐paraffinized in xylene and then rehydrated in a series of ethanol solutions. Sections were pretreated by microwave for five minutes on high mode and then 10 minutes on medium mode in citrate buffer (pH 6.5). Peroxidase activity was blocked with 3% H~2~O~2~‐methanol and sections were incubated with bovine serum albumin to eliminate non‐specific staining. Anti‐human LOX polyclonal antibodies (1:100; Proteintech) were applied and then sections were washed three times with phosphate buffered saline and incubated with secondary antibody (1:1000; Gene Co. Ltd., Chai Wan, Hong Kong) for another 30 minutes at room temperature. Following three five‐minute rinses in phosphate buffered saline, staining was completed with 10‐minute incubation with 3,3\'‐diaminobenzidine‐tetrahydrochloride solution. The sections were then counterstained with 0.1% hematoxylin and topped with a coverslip, and immunoreactive scores were recorded, as previously described.[19](#tca12645-bib-0019){ref-type="ref"}

Statistical analysis {#tca12645-sec-0012}
--------------------

Statistical analysis was performed using SPSS version 13.0 (SSPS Inc., Chicago, IL, USA). Correlations were assessed with the Spearman correlation coefficient or Pearson chi‐square test. Kaplan--Meier survival curves were generated and survival data were analyzed with the log‐rank test and Cox proportional hazards regression. *P* \< 0.05 was considered statistically significant.

Results {#tca12645-sec-0013}
=======

High LOX expression in colorectal cancer (CRC) specimens is associated with poor prognosis {#tca12645-sec-0014}
------------------------------------------------------------------------------------------

To identify LOX mRNA expression in CRC, qRT‐PCR analysis was performed in eight pairs of newly collected normal mucosa and matched tumor tissue specimens. Compared with the normal tissue specimens, LOX mRNA expression was upregulated in four CRC specimens and downregulated in the other four CRC specimens (Fig [1](#tca12645-fig-0001){ref-type="fig"}a). Because LOX has been reported to be both a tumor suppressor and a tumor promoter in CRC, and hypermethylation of the LOX promoter has been identified in some CRC cases, changes in LOX mRNA expression before and after 5‐aza‐dC treatment were detected in an HCT116 cell line. We found that 5‐aza‐dC treatment effectively increased LOX mRNA expression (Fig [1](#tca12645-fig-0001){ref-type="fig"}b). When the cohort was stratified by median relative LOX level, patients with higher LOX mRNA expression showed poor OS.

![Upregulation of LOX messenger RNA (mRNA) expression in colorectal cancer (CRC) is correlated with poor prognosis. (**a**) Quantitative real‐time PCR analysis of LOX mRNA level in eight fresh CRC and matched normal mucosa tissue specimens. (**b**) Relative expression of LOX in HCT116 cell line after5‐aza‐dC treatment. (**c**) Kaplan--Meier plots of overall survival of CRC patients stratified by LOX mRNA expression. Log‐rank test was performed to assess statistical significance. (![](TCA-9-785-g005.jpg "image")) normal tissue; (![](TCA-9-785-g001.jpg "image")) tumor tissue.](TCA-9-785-g004){#tca12645-fig-0001}

Nuclear localization of LOX is associated with poor prognosis {#tca12645-sec-0015}
-------------------------------------------------------------

To evaluate LOX protein expression in CRC and analyze the relationship between LOX protein expression and CRC development or progression, immunohistochemical analysis was performed using CRC tissue arrays. As shown in Figure [2](#tca12645-fig-0002){ref-type="fig"}a,b, normal tissues showed weak or mild positive staining (panels i--ii), while most CRC tissue specimens showed a low, medium, or high level of LOX protein expression (panels iii--vi). A significant portion of CRC specimens (84/201) were stained with nuclear LOX (panel iii--v). LOX protein intracellular nuclear localization was associated with prognosis in CRC patients. The 35‐month overall survival rates were 49.3% and 81.4% for patients with or without positive LOX nuclear staining, respectively (Fig [2](#tca12645-fig-0002){ref-type="fig"}c).

![Overexpression and intracellular localization of LOX in colorectal cancer (CRC) and their clinical significance. (**a**) Immunohistochemical analysis of LOX in CRC and normal mucosa tissue specimens. Representative images of (**i**) weak and (**ii**) mild LOX expression in normal tissue, (**iii**) low level expression of LOX in CRC, (**iv**) medium level LOX expression, (**v**) high level/nuclear expression and (**vi**) high level/cytoplasm expression LOX in CRC. (**b**) Box‐and‐whisker plots of LOX expression levels in normal mucosa and CRC tissues. A Kruskal--Wallis H test was performed to assess statistical significance. \*\*\**P* \< 0.001. (**c,d**) Kaplan--Meier plots of overall and disease‐free survival of CRC patients stratified by LOX intracellular localization. (**e**) Correlation of LOX nuclear localization and postoperative lung/hepatic metastasis in CRC. A Spearman rank coefficient test was performed to assess statistical significance.](TCA-9-785-g003){#tca12645-fig-0002}

Nuclear localization of LOX is correlated with lung/hepatic metastasis in CRC patients {#tca12645-sec-0016}
--------------------------------------------------------------------------------------

The associations between LOX nuclear localization and clinicopathological characteristics in CRC patients are shown in Table [1](#tca12645-tbl-0001){ref-type="table"}. Nuclear LOX expression was correlated with distant metastasis (*P* \< 0.05). Nuclear localization of LOX was significantly positively correlated with lung/hepatic metastasis, and the level of clinical metastasis markers, such as CEA, in CRC patients (*P* \< 0.05). Interestingly, nuclear LOX expression was also associated with the mucinous tumor type (*P* \< 0.05).

###### 

Correlations between LOX nuclear localization and clinicopathological features of CRC patients

  Variables                                           LOX nuclear staining   *P* [†](#tca12645-note-0003){ref-type="fn"}                
  --------------------------------------------------- ---------------------- --------------------------------------------- ------------ ----------------------------------------------------
  Age (year)[‡](#tca12645-note-0004){ref-type="fn"}   201                                                                               0.489
  ≤ 63                                                117                    70 (59.8%)                                    47 (40.2%)   
  \> 63                                               84                     47 (56.0%)                                    37 (44.0%)   
  Gender                                              201                                                                               0.396
  Male                                                114                    69 (60.5%)                                    45 (39.5%)   
  Female                                              87                     48 (55.2%)                                    39 (44.8%)   
  Tumor size (cm)                                     201                                                                               0.261
  ≤ 5 cm                                              137                    83 (60.6%)                                    54 (39.4%)   
  \> 5 cm                                             64                     34 (53.1%)                                    30 (46.9%)   
  TNM staging                                         201                                                                               0.536
  I                                                   19                     11 (57.9%)                                    8 (42.1%)    
  II                                                  76                     50 (65.8%)                                    26 (34.2%)   
  III                                                 84                     48 (57.1%)                                    36 (42.9%)   
  IV                                                  22                     8 (36.4%)                                     14 (63.6%)   
  Invasion                                            201                                                                               0.525
  T~1~                                                4                      1 (25.0%)                                     3 (75.0%)    
  T~2~                                                20                     11 (55.0%)                                    9 (45.0%)    
  T~3~                                                78                     46 (59.0%)                                    32 (41.0%)   
  T~4~                                                99                     59 (59.6%)                                    40 (40.4%)   
  No. of positive nodes                               201                                                                               0.58
  0                                                   99                     61 (61.6%)                                    38 (38.4%)   
  1--3                                                74                     38 (51.4%)                                    36 (48.6%)   
  \> 3                                                28                     18 (64.3%)                                    10 (35.7%)   
  Distal metastasis                                   201                                                                               **0.03** [\*](#tca12645-note-0002){ref-type="fn"}
  M~0~                                                179                    109 (54.2%)                                   70 (45.8%)   
  M~1~                                                22                     8 (36.4%)                                     14 (63.6%)   
  CEA level                                           201                                                                               **0.045** [\*](#tca12645-note-0002){ref-type="fn"}
  0--10 ng/mL                                         140                    88 (62.9%)                                    52 (37.1%)   
  \> 10 ng/mL                                         61                     29 (47.5%)                                    32 (52.5%)   
  Tumor type                                          201                                                                               **0.038** [\*](#tca12645-note-0002){ref-type="fn"}
  Non‐mucinous                                        186                    112 (60.2%)                                   74 (39.8%)   
  Mucinous[§](#tca12645-note-0005){ref-type="fn"}     15                     5 (33.3%)                                     10 (66.7%)   
  Lung metastasis                                     201                                                                               **0.025** [\*](#tca12645-note-0002){ref-type="fn"}
  No                                                  189                    113 (60.9%)                                   76 (39.1%)   
  Yes                                                 11                     3 (27.3%)                                     8 (72.7%)    
  Hepatic metastasis                                  201                                                                               **0.034** [\*](#tca12645-note-0002){ref-type="fn"}
  No                                                  184                    112 (58.7%)                                   72 (41.3%)   
  Yes                                                 17                     6 (35.3%)                                     11 (64.7%)   
  Tumor site[¶](#tca12645-note-0006){ref-type="fn"}   201                                                                               0.219
  Proximal colon                                      23                     11 (47.8%)                                    12 (52.2%)   
  Distal colon                                        91                     51 (56.0%)                                    40 (44.0%)   
  Rectum                                              87                     55 (63.2%)                                    32 (36.8%)   
  Differentiation                                     201                                                                               0.789
  Well                                                23                     14 (60.9%)                                    9 (39.1%)    
  Moderate                                            160                    92 (57.5%)                                    68 (42.5%)   
  Poor                                                18                     11 (61.1%)                                    7 (38.9%)    
  Ki67                                                153                                                                               0.617
  Negative                                            112                    66 (58.9%)                                    46 (41.1%)   
  Positive                                            41                     26 (63.4%)                                    15 (36.6%)   
  Pelvic cavity metastasis                            201                                                                               0.199
  No                                                  191                    113 (58.6%)                                   78 (41.4%)   
  Yes                                                 10                     4 (40.0%)                                     6 (60.0%)    
  CA242 level                                         201                                                                               0.718
  0--20 u/mL                                          149                    85 (57.0%)                                    64 (43.0%)   
  \> 20 u/mL                                          52                     32(61.5%)                                     20 (38.5%)   
  CA199 level                                         201                                                                               0.226
  0--39 U/mL                                          168                    94 (56.0%)                                    74 (44.0%)   
  \> 39 U/mL                                          33                     23 (69.7%)                                    10 (30.3%)   

Statistically significant.

χ2 test.

Median age at operation.

The mucinous type includes mucinous adenocarcinoma and signet ring cell carcinoma.

Proximal colon tumors develop in the cecum, ascending colon, hepatic flexure, or transverse colon; distal colon tumors develop in the splenic flexure, descending colon, or sigmoid colon; and rectal tumors develop in the rectosigmoid or rectum.

CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CRC, colorectal cancer; TNM, tumor node metastasis.

Nuclear localization of LOX is associated with postoperative lung/hepatic metastasis and poor disease‐free survival {#tca12645-sec-0017}
-------------------------------------------------------------------------------------------------------------------

Of the 201 patients in this series, 142 CRC patients underwent radical resection and were followed‐up routinely, particularly for postoperative local or distant relapse. Nuclear LOX expression was correlated with postoperative lung/hepatic metastasis (Fig [2](#tca12645-fig-0002){ref-type="fig"}e) and low disease‐free survival (Fig [2](#tca12645-fig-0002){ref-type="fig"}d).

YAP and TEAD4 mediates LOX expression in CRC {#tca12645-sec-0018}
--------------------------------------------

The Hippo signaling pathway is known to play a role in in the expansion of undifferentiated progenitor cells and the development of CRC. YAP protein is an important component of the Hippo pathway, and transcriptional factor proteins (TEADs) mediate most functions of YAP.[20](#tca12645-bib-0020){ref-type="ref"} As *CTGF* is a classic YAP target gene and has been reported to play a role in regulating LOX expression,[21](#tca12645-bib-0021){ref-type="ref"} possible correlations between YAP and LOX expression were analyzed in 45 primary human CRC specimens using qRT‐PCR (Fig [3](#tca12645-fig-0003){ref-type="fig"}a). The LOX mRNA expression level was related to the YAP mRNA level. In addition, knockdown of either YAP or TEAD4 induced downregulation of LOX protein and mRNA expression (Fig [3](#tca12645-fig-0003){ref-type="fig"}b--d).

![Regulation of LOX by YAP and TEAD4. (**a**) Correlation between YAP and LOX relative messenger RNA (mRNA) levels in 45 primary human colorectal cancer (CRC) specimens. The Spearman rank coefficient was used as a statistical measure of correlation. (**b**) Representative Western blot result of LOX protein level in the control LoVo cells and YAP knockdown cells. (**c--e**) Quantitative real‐time‐PCR and Western blot analysis of mRNA level of TEAD4 and LOX in LoVo cells with control pLKO.1 or TEAD4 short hairpin RNA virus.](TCA-9-785-g002){#tca12645-fig-0003}

Discussion {#tca12645-sec-0019}
==========

LOX was initially identified as an ECM enzyme that regulated the tensile strength of tissues.[11](#tca12645-bib-0011){ref-type="ref"} Some in vitro studies reported that the LOX gene was a tumor suppressor and its re‐expression could revert H‐Ras‐mediated transformation of NIH 3T3 fibroblasts.[22](#tca12645-bib-0022){ref-type="ref"} However, LOX mRNA expression is either upregulated or downregulated in some cancer types, including CRC. Our results showed that LOX expression is both increased and decreased in tumor tissues compared to the matched normal colon tissues. Loss of chromosome 5q14--5q31 and hypermethylation may be the cause of LOX downregulation in CRC.[17](#tca12645-bib-0017){ref-type="ref"}, [23](#tca12645-bib-0023){ref-type="ref"} To investigate whether promoter hypermethylation could decrease LOX expression, HCT116 cells were treated with 5‐aza‐dC, an inhibitor of DNA methylation. Hypermethylation occurred in the LOX promoter region as a result. LOX mRNA expression was significantly increased after 5‐aza‐dC treatment, suggesting that hypermethylation plays a role in downregulating LOX expression.

Previous studies have reported that the LOX protein is a metastasis promoter in breast, neck, and oral and oropharyngeal squamous cancers.[15](#tca12645-bib-0015){ref-type="ref"}, [24](#tca12645-bib-0024){ref-type="ref"} However, few studies have reported the relationship between LOX expression and CRC metastasis. Recently, Erler *et al*. showed that LOX expression was significantly elevated in tumor tissue compared to normal colon tissues, with the greatest increase observed in the metastatic tissue.[16](#tca12645-bib-0016){ref-type="ref"} Our results indicate that the tumor tissue immunoreactive score is significantly higher than in normal tissue. In addition, nuclear and cytoplasmic localization of LOX protein was detected in CRC cells. Recent studies have demonstrated that LOX plays novel intracellular roles, including its ability to regulate gene transcription, migration, and cell adhesion. These diverse functions have led researchers to hypothesize that LOX may play multiple roles in affecting both extracellular and intracellular cell function(s).[25](#tca12645-bib-0025){ref-type="ref"} In a previous study, LOX protein was processed extracellularly to produce a ∼30kDa active molecular form. The sequence of the proteolytic processing site in pro‐LOX resembled that of the fibrillary procollagen C‐terminal pro‐peptide processing site cleaved by procollagen C‐proteinase.[26](#tca12645-bib-0026){ref-type="ref"} Indeed, the propeptide contains a putative nuclear localization sequence,[27](#tca12645-bib-0027){ref-type="ref"} suggesting that it may be actively directed to the nucleus once released from the proenzyme, and has been shown to be capable of both repressing the oncogenic *bcl‐2* gene in breast cancer[28](#tca12645-bib-0028){ref-type="ref"} and inhibiting FGF‐2 signaling in prostate cancer.[27](#tca12645-bib-0027){ref-type="ref"}

However, our data fail to support the hypothesis that LOX nuclear localization might act as a tumor suppressor in CRCs. We found that LOX nuclear localization is associated with lung/hepatic metastasis and poor OS. Nuclear LOX expression is correlated with elevated CEA concentration. A recent study showed that LOX mRNA expression is associated with diffuse cytoplasmic expression of CEA, which is consistent with our finding.[29](#tca12645-bib-0029){ref-type="ref"} LOX nuclear localization is correlated with postoperative lung/hepatic metastasis and poor DFS in patients who undergo radical resection. We conclude that LOX may act as a tumor promoter in CRC, partially by translocation into the nucleus, although the mechanism needs to be further explored.

LOX expression induced by TGF‐β,[30](#tca12645-bib-0030){ref-type="ref"} TNF‐α,[31](#tca12645-bib-0031){ref-type="ref"} and IFN‐γ[24](#tca12645-bib-0024){ref-type="ref"}, [32](#tca12645-bib-0032){ref-type="ref"} has been implicated in earlier studies. LOX expression is induced under hypoxic conditions through hypoxia‐inducible factor‐1 transcription factor binding to a functional hypoxia‐responsive element in the promoter region.[24](#tca12645-bib-0024){ref-type="ref"} Crosstalk of the signaling pathway is common in tumor genesis and development. The Hippo pathway plays a role in the development of CRC.[33](#tca12645-bib-0033){ref-type="ref"} YAP overexpression is frequently detected in CRC and is correlated with poor prognosis.[34](#tca12645-bib-0034){ref-type="ref"} Earlier studies have reported that knocking down *CTGF*, a direct target gene of YAP and TEADs, plays a role in LOX expression.[21](#tca12645-bib-0021){ref-type="ref"} Bioinformatics studies have shown potential TEAD protein binding sites on the promoter region of LOX. We found that knockdown of both YAP and TEAD4 induces LOX downregulation, suggesting that LOX is a potential target gene of YAP and TEAD4.

In summary, although recent studies have reported the intracellular functions of LOX, no studies of the possible association between LOX nuclear localization and the clinicopathological features of CRC have been published. The results obtained in this study have for the first time revealed a significant correlation between the LOX nuclear localization and synchronous or postoperative lung/hepatic metastasis. In addition, LOX intracellular localization was found to be a prognostic marker of a worse outcome in CRC patients. The Hippo pathway plays a role in regulating LOX expression in CRC. However, whether LOX is a direct target gene of TEAD4/YAP needs to be further clarified.
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